Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
61 Leser
Artikel bewerten:
(0)

Research and Markets - Global Professional Diagnostics Market - Analysis, Technologies & Forecasts to 2020 - Key Vendors are Danaher, Roche Diagnostics & Siemens Healthcare

DUBLIN, Nov 16, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Professional Diagnostics Market 2016-2020" report to their offering.

The report forecasts the global professional diagnostics market to grow at a CAGR of 6.76% during the period 2016-2020.

The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One of latest trends in the market is launch of novel tests in lung and colon cancer influencing the market growth of PD devices. Targeted genetic testing for cancer that is available to molecular pathologists is a unique combination of ease of use, cost-effectiveness, reliability, and sensitivity. Multiplexed assays reduce the cost and turnaround time compared with existing methods by allowing the user to simultaneously analyze the relevant oncogenes. The two test panels help in personalizing treatment and improving patient care with rapid analysis of clinically actionable mutations occurred in lung and colon cancer.

According to the report, one of the primary drivers in the market is increasing industrial partnerships driving the growth of the market. Companies of different financial caliber compete in the medical devices, which includes professional diagnostics devices. Some are more specialized with respect to particular markets, and others have higher financial resources. New companies have entered the areas of blood coagulation, safety-engineered devices, and life sciences. Established companies have broadened their business activities into medical technology. These initiatives aim to leverage each other's unique selling propositions (USPs), such as strong customer bases, technology and strong financial and R&D capabilities. This has resulted in many partnerships between companies to increase their market share.

Further, the report states that one major challenge in the market is professional challenges in clinical microbiology and infectious diseases in Europe.

Key vendors:

  • Abbott Diagnostics
  • Danaher
  • Roche Diagnostics
  • Siemens Healthcare
  • Thermo Fisher Scientific

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Market segmentation by product

Part 07: Market segmentation by end-user

Part 08: Geographical segmentation

Part 09: Market drivers

Part 10: Impact of drivers

Part 11: Market challenges

Part 12: Impact of drivers and challenges

Part 13: Market trends

Part 14: Vendor landscape

Part 15: Key vendor analysis

Part 16: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/kn76pj/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.